Silence Therapeutics Plc
SLN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SLN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SLN
Silence Therapeutics Plc (SLN) is a clinical-stage biotechnology company focused on developing siRNA-based therapeutics for diseases with significant unmet need, with its most advanced candidate, divesiran, targeting lipoprotein(a) elevation.
Key risk: No product revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$834.1M
Cash Runway
—
Lead Asset
Divesiran (Phase 2)
Next Catalyst
Phase2_Topline · Sep 30, 2026Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 6 clinical trials · 1 catalyst for Silence Therapeutics Plc.
Silence Therapeutics Plc (SLN) is a clinical-stage biotechnology company focused on developing siRNA-based therapeutics for diseases with significant unmet need, with its most advanced candidate, divesiran, targeting lipoprotein(a) elevation.
- Silence Therapeutics is developing siRNA-based product candidates, with divesiran being the lead candidate in a Phase 2 study for elevated lipoprotein(a) [sec].
- The company has not achieved profitability since inception and expects to incur net losses in the future [sec_mda · as of 2026-05-07].
- As of June 30, 2026, the company reported cash and equivalents of $72.1M, with no revenue and a net loss of $12.3M for the period [sec].
- The company relies on additional capital, including non-dilutive strategic collaborations and equity or debt financings, to fund operations [sec · filed 2024-03-13].
- Silence Therapeutics has a history of operating losses and expects to require significant additional funding to continue development and potential commercialization of its product candidates [sec · filed 2024-03-13].
What works
- The company has a proprietary siRNA platform that may enable the development of novel therapeutics for a range of diseases [sec].
- Divesiran, the lead candidate, is in a Phase 2 study for elevated lipoprotein(a), a condition with limited treatment options and significant cardiovascular risk [catalyst].
- The company has secured capital through private placements and collaborations, indicating some investor and partner confidence in its technology [sec · filed 2024-03-13].
What to weigh
- Silence Therapeutics has never generated product revenue and does not expect to for many years, if ever [sec · filed 2024-03-13].
- The company has a history of net losses and expects to continue incurring losses, requiring additional funding that may not be available on acceptable terms [sec_mda · as of 2026-05-07].
- Clinical development carries high risk of failure, and success in preclinical or early clinical trials does not guarantee later trial success [sec · filed 2024-06-27].
- The company may need to raise additional capital through dilutive equity offerings or debt, which could significantly dilute existing shareholders [sec · filed 2024-03-13].
From the filings
Quoted directly from source documents.
The company has not achieved profitability and expects to incur net losses.
“We have not achieved profitability on an annual basis since our inception, and we expect to incur net losses in the future.”
SEC filings · May 7, 2026
The company does not anticipate generating product revenues for the foreseeable future.
“We do not anticipate generating revenues from sales of products for the foreseeable future, if ever.”
SEC filings · March 13, 2024
The company will require additional capital to fund operations and clinical trials.
“We will require additional financial resources to continue the ongoing development of our product candidates and pursue our business objectives.”
SEC filings · March 13, 2024
Clinical trial results are preliminary and may not be indicative of final outcomes.
“preliminary or topline results are based on a preliminary analysis of key efficacy and safety data; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results”
SEC filings · June 27, 2024
Catalyst timeline
- 2026-09-30 · Phase2_Topline · divesiran — Phase 2 Readout: divesiran — Topline results from the Phase 2 study of divesiran in patients with elevated lipoprotein(a) are expected, which will be a key data point for the program's advancement.
Risks & what to watch (4)›
Key risks
- No product revenue — The company has no approved products and does not expect to generate product revenue for many years, if ever [sec · filed 2024-03-13].
- Clinical trial failure risk
- Need for additional capital
- History of losses
What to watch
- Topline data from the Phase 2 study of divesiran for elevated lipoprotein(a), expected around September 30, 2026 [catalyst].
- Updates on the company's cash position and any new financing or collaboration agreements [sec].
- Progress of other pipeline candidates, including those in Phase 1/2 studies [catalyst].
- Regulatory developments and any updates on the company's ability to achieve profitability or generate revenue [sec].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Silence Therapeutics Plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Silence Therapeutics Plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 1.77 · 0% dilution
Lead: Phase 3
3 candidates
1 upcoming, next in ~31d
0 buys · 17 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
50
Total value held
$39.9M
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 1,246,107 | $6.6M |
| millennium management llc | 1,074,191 | $5.7M |
| great point partners llc | 1,020,489 | $5.4M |
| tetragon partners gp ltd | 630,161 | $3.3M |
| 5am venture management, llc | 476,200 | $2.5M |
| jones hill capital lp | 301,604 | $1.6M |
| ubs group ag | 246,937 | $1.3M |
| boothbay fund management, llc | 209,088 | $1.1M |
| blackrock, inc. | 204,777 | $1.1M |
| bank of montreal /can/ | 202,901 | $1.1M |
Showing top 10 of 50 institutional holders of Silence Therapeutics Plc. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 6.0%
- Days to cover
- 5.1
- Shares short
- 2,156,496
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SLN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Silence Therapeutics Plc?
Silence Therapeutics Plc (SLN) is a clinical-stage biotechnology company focused on developing siRNA-based therapeutics for diseases with significant unmet need, with its most advanced candidate, divesiran, targeting lipoprotein(a) elevation.
What is Silence Therapeutics Plc's lead drug candidate?
Silence Therapeutics Plc's most advanced tracked candidate is Divesiran (Phase 2) for Polycythemia vera (PV).
What is Silence Therapeutics Plc's next catalyst?
Silence Therapeutics Plc's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: divesiran" — expected September 30, 2026.
Who is the CEO of Silence Therapeutics Plc?
Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D is the chief executive officer of Silence Therapeutics Plc (SLN).
Where is Silence Therapeutics Plc headquartered?
Silence Therapeutics Plc (SLN) is headquartered in London, United Kingdom.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.